HCOs

Views & Analysis

On 28 September 2022, the international and European self-regulatory bodies for the research-based pharmaceutical industry (I

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.